← Back
Data updated: Mar 29, 2026
PHARMACIA AND UPJOHN
DermatologyInfectious DiseaseRespiratory
Big Pharma
PHARMACIA AND UPJOHN is a major pharmaceutical company focused on Dermatology, Infectious Disease, Respiratory.
1942
Since
58
Drugs
-
Trials
28
Approved (2yr)
Key Drugs
No active drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Dermatology 36%
4 drugs
Infectious Disease 27%
3 drugs
Respiratory 18%
2 drugs
Immunology 9%
1 drugs
Metabolic 9%
1 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Sanofi big-pharma
Metabolic, Infectious Disease, Immunology, Respiratory
Pfizer big-pharma
Infectious Disease, Dermatology, Immunology
Merck big-pharma
Infectious Disease, Immunology, Metabolic
Johnson & Johnson big-pharma
Immunology, Infectious Disease, Metabolic
MALLINCKRODT specialty
Dermatology, Metabolic, Immunology, Respiratory
Discontinued (50)
HEPARIN SODIUM MEDROL CYKLOKAPRON CORTISONE ACETATE AZULFIDINE PENICILLIN G SODIUM ANSAID OGEN EMCYT DELTASONE MYCIFRADIN PROTAMINE SULFATE DEPO-TESTADIOL LUNELLE ZEFAZONE ORINASE DIAGNOSTIC TOLINASE ADRUCIL PANMYCIN NEO-CORTEF NEO-MEDROL ACETATE ZEFAZONE IN PLASTIC CONTAINER FOLEX PFS HALOTESTIN HYLOREL CORTEF ACETATE ORINASE PROSTIN F2 ALPHA FLUIDIL ALBAMYCIN ALPHADROL OXYLONE MEDROL ACETATE U-GENCIN DELTA-CORTEF BACIGUENT DIZAC CALMURID HC TYMTRAN CARDRASE FOLEX NORMIFLO NEO-MEDROL NEO-DELTA-CORTEF MYCITRACIN VANCOR FEMINONE UTICILLIN VK BERUBIGEN E-MYCIN E
Company Info
- First Approval
- 1942-02-05
- Latest
- 2025-11-04
- Applications
- 72